AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7930256
Drug: Enalaprilat (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (0.6 micrograms/min per 100 ml tissue volume)
Trial: 7930256
Drug: NG‐monomethyl‐L‐arginine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (n = 10)
Trial: 3086359
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion (8 mg in 1 min followed by 12 mg in 3 h)
Trial: 3086359
Drug: Testosterone undecanoate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate, 40 mg three times a day by mouth
Trial: 22488002
Drug: Soybean oil-based
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil-based parenteral nutrition (Intralipid)
Trial: 22488002
Drug: Olive oil-based
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil-based parenteral nutrition (ClinOleic)
Trial: 21040626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 97 mg L-theanine and 40 mg caffeine
Trial: 18349061
Drug: Daily PTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PTH
Trial: 17703634
Drug: Telmisartan/Hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Hydrochlorothiazide combination
Trial: 25651363
Drug: ZS-9 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZS-9 3 g three times daily for 2 days
Trial: 25651363
Drug: ZS-9 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZS-9 10 g three times daily for 2 days
Trial: 26011677
Drug: ZS-9 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZS-9 10 g
Trial: 11131448
Drug: Etidronate 400
RxNorm normalized name: etidronate 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 400 mg/day for 14 days every 3 months for at least 1 year with supplemental calcium
Trial: 8886085
Drug: Hyalectin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyalectin 20 mg
Trial: 30306831
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment for 8 weeks
Trial: 2708190
Drug: Dichloroacetate infusion
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate infusion
Trial: 31767215
Drug: internet delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet delivered cognitive behaviour therapy (iCBT) for eight weeks, five sessions (n=150)
Trial: 16442406
Drug: Intravenous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous low-dose vitamin K
Trial: 14872180
Drug: Cold-adapted trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted trivalent intranasal influenza virus vaccine (CAIV)
Trial: 7995183
Drug: Max-EPA (triglyceride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max-EPA (triglyceride preparation)
Trial: 2741263
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment only
Trial: 2741263
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment plus 5-fluorouracil 5% ointment
Trial: 2741263
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment and adjuvant 5-fluorouracil 2% painting
Trial: 22219315
Drug: 6 μg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 μg reduced-dose seasonal trivalent influenza vaccine
Trial: 22219315
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg conventional seasonal trivalent influenza vaccine
Trial: 7570406
Drug: Asthma self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma self-management programme (four 2.5 hour education sessions at weekly intervals)
Trial: 466952
Drug: Glucagon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (2 mg intravenous)
Trial: 27607861
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (saline)
Trial: 26789096
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (250 mg)
Trial: 26789096
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (500 mg)
Trial: 19996931
Drug: High-stringency CD8-depleted
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-stringency CD8-depleted DLI (starting dose: 1 x 10(6) CD4 cells/kg for unrelated, 3 x 10(6) CD4 cells/kg for related)
Trial: 16027402
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium 100 mg every 8 hours for 7 days
Trial: 12412994
Drug: UDCA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA plus suplatast tosilate (300 mg/day tid)
Trial: 12412994
Drug: UDCA alone
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA alone (600 mg/day tid)
Trial: 30650259
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin (400 mg)
Trial: 23669513
Drug: Early limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early limited formula (10 mL formula by syringe after each breastfeeding, discontinued when mature milk production began)
Trial: 20972878
Drug: Low-intensity resistance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity resistance training (LSR) at 50% of one repetition maximum for 10 weeks, performed twice a week with five sets of ten repetitions and 30 seconds inter-set rest period
Trial: 18984831
Drug: Very early
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very early mobilization and task-oriented physical therapy
Trial: 12620953
Drug: Diltiazem (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (2 micro g x kg(‐1) x min(‐1))
Trial: 12620953
Drug: Dopamine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (2.5 micro g x kg(‐1) x min(‐1))
Trial: 7473239
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of BCAA (6 g l-1)
Trial: 7473239
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of BCAA (18 g l-1)
Trial: 29999208
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to the tibia bone for 100 seconds prior to PPCI and at 24 and 72 hours post-PPCI.
Trial: 26330561
Drug: Early home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early home-based group education on renal replacement therapy (RRT) options
Trial: 22464760
Drug: 17β‐estradiol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17β‐estradiol (4 mg/d)
Trial: 18356842
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day CLA (50:50 cis-9, trans-11:trans-10, cis-12) and 3 g/day n-3 LC-PUFA
Trial: 18356842
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day control fat
Trial: 12666963
Drug: Metronidazole 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 25% dental gel (ELYZOL DENTAL GEL) applied on day 0 and day 7
Trial: 12666963
Drug: Scaling adjunctive
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling adjunctive to metronidazole 25%
Trial: 17852789
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of clopidogrel until 30 days after OPCAB surgery
Trial: 15681270
Drug: Spinal Manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Manipulative Therapy (MT)
Trial: 11943636
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (15 mg iron/day) for 3 months
Trial: 11943636
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (15 mg iron/day) for 6 months
Trial: 11943636
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (15 mg iron/week) for 6 months
Trial: 8097332
Drug: Guanfacine (GUA)
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine (GUA) 1.5 mg IV
Trial: 3800343
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g mezlocillin every 8 h
Trial: 30138389
Drug: Antithrombotic medications
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic medications (including aspirin-dipyridamole plus clopidogrel, rivaroxaban plus aspirin, warfarin plus aspirin, warfarin plus aspirin and clopidogrel)
Trial: 30138389
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus aspirin and clopidogrel
Trial: 30138389
Drug: Dabigatran monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran monotherapy
Trial: 30138389
Drug: Dabigatran plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran plus aspirin
Trial: 30138389
Drug: Users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Users of antithrombotic medication
Trial: 21709087
Drug: Dihydroartemisinin‐piperaquine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin‐piperaquine with 200 ml milk containing 6.4 g fat (n = 15)
Trial: 11111997
Drug: University of
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: University of Wisconsin (UW) preservation solution (n = 20)
Trial: 11111997
Drug: Celsior preservation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celsior preservation solution (n = 21)
Trial: 3255485
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Control group)
Trial: 26886017
Drug: Pegfilgrastim administered
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administered the same day as chemotherapy
Trial: 26886017
Drug: Pegfilgrastim administered
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim administered the next day after chemotherapy
Trial: 24128381
Drug: Smoking-cessation treatment
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smoking-cessation treatment (SCT) including weekly individual counseling, extended-release bupropion (300 mg/day), nicotine inhaler, and contingency management for smoking abstinence
Trial: 15782318
Drug: 10 ppm
RxNorm normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ppm inhaled nitric oxide (iNO)
Trial: 12424485
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g dipyrone in 10 ml saline
Trial: 12424485
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous injection of 10 ml saline)
Trial: 9495568
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (0.05 g/day) for six months
Trial: 9495568
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (0.05 g/day) + Medroxyprogesterone acetate (MPA; 10 mg/day, per orally for the last ten days)
Trial: 24417987
Drug: aranidipine 5-20
RxNorm normalized name: lercanidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aranidipine 5-20 mg/d
Trial: 24417987
Drug: retard-released felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retard-released felodipine 5-10 mg/d
Trial: 24417987
Drug: aranidipine 20
RxNorm normalized name: lercanidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aranidipine 20 mg/d
Trial: 19487960
Drug: Single-agent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent therapy (gemcitabine or vinorelbine)
Trial: 15142327
Drug: Lower dosage
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dosage group (9 daily sessions)
Trial: 9486672
Drug: Flurandrenolide tape
RxNorm normalized name: Flurandrenolide Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurandrenolide tape (4 microg/cm2) applied once daily for up to 16 hours
Trial: 9486672
Drug: Diflorasone diacetate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflorasone diacetate ointment (0.05%) applied twice daily
Trial: 16298650
Drug: No antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibody induction (Control)
Trial: 2974715
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cilazapril and propranolol
Trial: 2974715
Drug: Cilazapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5 mg day‐1)
Trial: 2974715
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg day‐1)
Trial: 26073770
Drug: Web-assisted calprotectin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-assisted calprotectin-based treatment algorithm (IBD-live)
Trial: 16607097
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg/day
Trial: 15162251
Drug: Iron supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplement of 47 mg per day
Trial: 15162251
Drug: Dietary plan
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dietary plan rich in iron providing 26 mg per day
Trial: 10931747
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of rhGH (5, 10 or 15 mg per 1.5 ml)
Trial: 8340985
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic cream, eutectic mixture of local anesthetics (EMLA)
Trial: 26812786
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (tapered over 14 days)
Trial: 26812786
Drug: Intratympanic methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic methylprednisolone (40 mg/mL, injected twice a week for 2 weeks)
Trial: 24988909
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (n=97)
Trial: 18822733
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate hydrogel (1 mL/cm2)
Trial: 16236845
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice daily for 10 days
Trial: 7757984
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (cisplatin 80 mg/m2 i.v. on day 1, vindesine 3 mg/m2 i.v. on days 1 and 8, with or without mitomycin 8 mg/m2 i.v. on day 1)
Trial: 7216093
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release iron preparations
Trial: 7216093
Drug: Quick release
RxNorm normalized name: Zinc 50 mg + Vitamin C Quick Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quick release iron preparations
Trial: 7216093
Drug: All oral
RxNorm normalized name: Exall Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All oral iron preparations
Trial: 23635552
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg orally daily and rapamycin 2 mg orally daily (4 weeks on, 2 weeks off)
Trial: 15990827
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) at a loading dose of 70 mg/kg 2 hours before and 35 mg/kg at 4-hour intervals for a total of 24 hours after the procedure
Trial: 31421008
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC)
Trial: 8884623
Drug: Intravenous indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous indomethacin 50 mg
Trial: 1868973
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole, administered intravenously 4 times a day
Trial: 6354530
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg) + Naloxone (0.2 mg/kg i.v.)
Trial: 29071072
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy (HFNT)
Trial: 26802156
Drug: Cediranib 45
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 45 mg once daily and placebo (C)
Trial: 22334456
Drug: sorafenib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib at a dose of 400 mg twice daily
Trial: 19103363
Drug: Low- to
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low- to mid-potency topical steroids (short-term therapy for 2-4 weeks)
Trial: 19103363
Drug: Topical calcipotriene
RxNorm normalized name: calcipotriene Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriene (calcipotriol), pimecrolimus, or tacrolimus (long-term therapy)
Trial: 9798024
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice a day for 14 days)
Trial: 9798025
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice a day for 14 days)
Trial: 7697951
Drug: MK-0591 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 (250 mg)
Trial: 2507831
Drug: Special precautions
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special precautions (topical lidocaine by inhalation, bronchoscope through endotracheal tube)
Trial: 322635
Drug: Ethanol (1.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (1.32 ml/kg of body weight)
Trial: 16430312
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of ximelagatran 48mg every 12 hours for 5 days
Trial: 16430312
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ximelagatran 48mg on day 6
Trial: 16430312
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of ximelagatran
Trial: 14667010
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fissure sealant, received oral health education)
Trial: 10945014
Drug: Vinorelbine (monotherapy)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (monotherapy)
Trial: 19940281
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen treatment
Trial: 1582503
Drug: AR content
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR content (greater than or equal to 10 pmol/g)
Trial: 27872111
Drug: Ultrasound tailored
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound tailored treatment (disclosure of the ultrasound diagnosis)
Trial: 22221670
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy (one session per week)
Trial: 22221670
Drug: Improvisational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improvisational music therapy (three sessions per week)
Trial: 19781847
Drug: Vardenafil 5
RxNorm normalized name: vardenafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 5 mg/d at bedtime
Trial: 9141524
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetrorelix for 5 days followed by 2 x 1 mg/day
Trial: 9141524
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetrorelix for 5 days followed by 1 mg/day